Biogen Alzheimer's drug gets U.S. FDA staff backing, shares jump 40%
By Deena Beasley and Manojna Maddipatla (Reuters) - Biogen Inc has shown 'exceptionally persuasive' evidence that its experimental Alzheimer's disease drug is effective, U.S. Food and Drug Administration staff said on Wednesday, elevating its chances of a swift approval and sending company shares soaring
By Deena Beasley and Manojna Maddipatla
(Reuters) - Biogen Inc has shown "exceptionally persuasive" evidence that its experimental Alzheimer's disease drug is effective, U.S. Food and Drug Administration staff said on Wednesday, elevating its chances of a swift approval and sending company shares soaring.
An FDA approval could come by March, which would make the drug, aducanumab, the first new treatment for the disease in decades and the first that appears to be able to slow progression of the fatal, mind-wasting condition that affects millions of people.
Biogen's shares jumped $97.02, or nearly 40%, to $344.99.
The agency's documents were released ahead of a meeting on Friday of outside experts who will review, and decide whether to recommend approval of, aducanumab, an antibody designed to remove amyloid plaques from the brain.
"Briefing documents suggests a positive Advisory Committee vote, which bodes well for approval," Guggenheim analyst Yatin Suneja said in a research note.
FDA drug reviewers said results from one pivotal trial of aducanumab were persuasive and strongly positive. They acknowledged that a second large trial did not succeed, but maintained that it did not detract from the findings of the positive study. The FDA is not obligated to abide by its expert panel recommendations, but typically does.
Cambridge, Massachusetts-based Biogen in October last year revived its plans to seek approval for aducanumab, months after it had said that an independent futility analysis of the two studies showed they were unlikely to succeed.
Biogen said it changed plans after a new analysis showed a high dose of the drug could slow the disease's progression.
The FDA staff said data from one of the trials "provides the primary evidence of effectiveness as a robust and exceptionally persuasive study demonstrating" a clinically meaningful treatment effect.
The drug was jointly developed with Japan's Eisai Co Ltd, whose shares jumped 45%.
(Additional reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli and Bill Berkrot)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
By Chuck Mikolajczak NEW YORK (Reuters) - A gauge of global stocks hit a record and oil prices jumped on Monday as the newest positive data for a potential COVID-19 vaccine and signs of economic recovery in Asia boosted sentiment. U.S. stocks advanced, with the Dow Industrials setting a record as it neared the 30,000 mark for the first time, after pharma company Moderna said its prospective vaccine was 94.5% effective in preventing the illness, which has crushed economies across the globe
By Anirban Sen and Joshua Franklin (Reuters) - Airbnb Inc's initial public offering (IPO) registration showed on Monday that the home rental startup turned a profit in the third quarter despite the COVID-19 pandemic, as it gears up for one of the most anticipated stock market debuts in recent years. The filing, published ahead of Airbnb's anticipated stock market debut in December, showed a dramatic recovery in its fortunes, after the coronavirus outbreak dragged down its core home rental business during the first half of the year. The slump forced it to lay off 25% of its workforce in May, suspend marketing activities for the year and seek $2 billion (£1.5 billion) emergency funding from investors, including Silver Lake and Sixth Street Partners, at a valuation of $18 billion
By David Lawder WASHINGTON (Reuters) - U.S. President-elect Joe Biden said on Monday the United States needed to negotiate with allies to set global trading rules to counter China's growing influence but declined to say whether he would join a new China-backed Asian trade pact signed on Sunday.